Pegaspargase

From Anvita Health Wiki

Contents 1 Introduction 2 Indications 3 Contraindications 4 Dosage 5 Adverse-effects 6 Drug-interactions 7 More General Terms 8 Additional Terms 9 References

Introduction

• Tradename: Oncaspar.

Indications

• acute lymphoblastic leukemia in patients who would benefit from L-asparaginase, but have developed hypersensitivity to native forms of L-asparaginase

Contraindications

• pancreatitis
• significant hemorrhagic events with prior L-aspariginase therapy

Dosage

• dosage individualized
• IM administration may decrease risk of anaphylaxis

• Injection: ( preservative-free) 750 units/ mL.

Adverse-effects

• common (> 10%)

• hypersensitivity

• anaphylaxis, bronchospasm, dyspnea, urticaria, arthralgia, erythema, induration, pain, tenderness, lip swelling, pancreatitis (may be fulminant & fatal)

• increased serum amylases & lipase
• abnormal liver function tests
• jaundice
• ascites
• hypoalbuminemia
• fatty liver
• liver failure

• less common (> 5%)

• rash, erythema, edema, pain, fever/ chills, urticaria, dyspnea, bronchospasm
• emetic potential mild

• not common (1-5%)

• hypotension, tachycardia, thrombosis, abdominal pain, disseminated intravascular coagulation, decreased fibrinogen, hemolytic anemia, leukopenia, pancytopenia, thrombocytopenia, increased thromboplastin

• myelosuppression

• WBC mild, platelets mild
• onset 1 days
• nadir 14 days
• recovery 21 days

• adults have some higher incidence of adverse effects than children

Drug-interactions

• methotrexate (may decrease antineoplastic effect if given immediately prior to methotrexate)
• vincristine (may increase toxicity)
• prednisone (may increase hyperglycemic effect)
• may increase bleeding in patients receiving warfarin, NSAIDs, heparin or dipyridamole

More General Terms

• L-asparaginase
• antineoplastic agent (chemotherapeutic agent)

Additional Terms

• asparaginase (Elspar)

References

Kaiser Permanente Northern California Regional Drug  Formulary, 1998

pegaspargase (Oncaspar, PEG-L-asparaginase)